Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
FDA expanded EVO/EVO+ age indication, preliminary Q1 sales exceeded $90M with China rebound and Americas growth, Q1 results due 2026-05-13, and shares remain up about 32% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin rebound ⢠Cash burn ⢠Strong liquidity STAA posted a sharp quarterly profitability rebound with strong liquidity, but it is still burning cash and remains weighed down by weak annual capital efficiency and a rich sales multiple.
Price Behavior
Key Price Behavior Insights: ⢠Downtrend intact ⢠Bounce on support ⢠Capped upside Support Level: $27.0-$27.8 Resistance Level: $28.7-$29.3 Over the last month, STAA has weakened from $31.21 to $27.76, with a bounce off $26.55 offering only near-term support while $28.7-$29.3 remains a stubborn resistance band.
AI Summary
STAA has evolved from a broken-growth story into a self-help turnaround with strong liquidity and clear margin repair, but the investment case remains capped until growth re-accelerates beyond China and free cash flow turns sustainably positive, making execution on U.S./Brazil expansion the key catalyst and biggest risk.
Description
STAAR Surgical Company designs, manufactures and sells implantable intraocular lenses and the delivery systems used to place them, along with preloaded cataract lenses, injector components and related surgical instruments. Its products, which address refractive errors and cataract treatment, are marketed primarily to ophthalmologists and surgical centers through a mix of direct sales forces and distributor networks across North America, Europe and Asia. The company was founded in 1982 and is headquartered in Lake Forest, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | STAA | STAAR Surgical Company | FDA expanded EVO/EVO+ age indication, preliminary Q1 sales exceeded $90M with China rebound and Americas growth, Q1 results due 2026-05-13, and shares remain up about 32% over 21 trading days. | Closed | +5.9% |
| Apr 10 | Apr 17 | STAA | STAAR Surgical Company | STAAR Surgical has a fresh revenue surprise and momentum: preâannounced Q1 net sales above ~$90M drove a ~25% twoâday spike, and FDA expansion of EVO/EVO+ ICL indication (21â60 years) broadens its market. Shares are ~42% above their 21âday mean, with strong volume and activist/institutional buying, making STAA a highâvelocity nearâterm trade around the formal earnings release. | Closed | -5.1% |